The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Fluoxetine affords robust neuroprotection in the postischemic brain via its anti‐inflammatory effect
Abstract
Fluoxetine is a selective serotonin reuptake inhibitor that is widely used in the treatment of major depression including after stroke. In this study, we tested whether fluoxetine protects neuronal death in a rat cerebral ischemia model of middle cerebral artery occlusion (MCAO). The administration of fluoxetine intravenously (10 mg/kg) at 30 min, 3 hr, or 6 hr after MCAO reduced infarct volumes to 21.2 ± 6.7%, 14.5 ± 3.0%, and 22.8 ± 2.9%, respectively, of that of the untreated control. Moreover, the neuroprotective effect of fluoxetine was evident when it was administered as late as 9 hr after MCAO/reperfusion. These neuroprotective effects were accompanied by improvement of motor impairment and neurological deficits. The fluoxetine‐treated brain was found to show marked repressions of microglia activation, neutrophil infiltration, and proinflammatory marker expressions. Moreover, fluoxetine suppressed NF‐κB activity dose‐dependently in the postischemic brain and also in lipopolysaccharide‐treated primary microglia and neutrophil cultures, suggesting that NF‐κB activity inhibition explains in part its anti‐inflammatory effect. These results demonstrate that curative treatment of fluoxetine affords strong protection against delayed cerebral ischemic injury, and that these neuroprotective effects might be associated with its anti‐inflammatory effects. © 2008 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ischemic Cell Death in Brain Neurons
Lipton, P. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.4.1431 · Cited by 3,043
Integrating cell-signalling pathways with NF-κB and IKK function
Perkins, N. D. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2083 · Cited by 2,350
Imai, Y., Ibata, I., Ito, D., Ohsawa, K., & Kohsaka, S. (1996) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.1112 · Cited by 872 · cited 2×
“Brain sections were prepared 2 days after reperfusion, and stained with antibody against Iba-1 (a marker of cells of myeloid origin) (Imai et al., 1996), Mac2, a marker of activated resident microglia (Lalancette-Hebert et al., 2007), and MPO (a neutropil marker).”
Method
Cited by
Depression as a Microglial Disease
Yirmiya, R., Rimmerman, N., & Reshef, R. (2015) · Trends in Neurosciences · doi:10.1016/j.tins.2015.08.001 · Cited by 944
Chollet, F., Tardy, J., Albucher, J.-F., Thalamas, C., Berard, E., Lamy, C., Bejot, Y., Deltour, S., Jaillard, A., Niclot, P., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70314-8 · Cited by 925
Post-stroke depression: Mechanisms and pharmacological treatment
Villa, R. F., Ferrari, F., & Moretti, A. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.11.005 · Cited by 532
ROS and Brain Diseases: The Good, the Bad, and the Ugly
Popa-Wagner, A., Mitran, S., Sivanesan, S., Chang, E., & Buga, A.-M. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/963520 · Cited by 427
Post‐stroke depression: mechanisms, translation and therapy
Loubinoux, I., Kronenberg, G., Endres, M., Schumann‐Bard, P., Freret, T., Filipkowski, R. K., Kaczmarek, L., & Popa‐Wagner, A. (2012) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2012.01555.x · Cited by 315
Loftis, J. M., Huckans, M., & Morasco, B. J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.11.015 · Cited by 252
Anti-inflammatory effects of fluoxetine in lipopolysaccharide(LPS)-stimulated microglial cells
Liu, D., Wang, Z., Liu, S., Wang, F., Zhao, S., & Hao, A. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.04.033 · Cited by 221
Fluoxetine protects neurons against microglial activation-mediated neurotoxicity
Zhang, F., Zhou, H., Wilson, B. C., Shi, J.-S., Hong, J.-S., & Gao, H.-M. (2012) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(11)70066-9 · Cited by 123
Imipramine attenuates neuroinflammatory signaling and reverses stress-induced social avoidance
Ramirez, K., Shea, D. T., McKim, D. B., Reader, B. F., & Sheridan, J. F. (2015) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.01.016 · Cited by 108
Tang, M.-M., Lin, W.-J., Pan, Y.-Q., & Li, Y.-C. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00255 · Cited by 73
“Among the candidate pathways which could control microglial response, CX3CL1/CX3CR1 signaling provides insights into microglianeuron interactions (Sheridan and Murphy, 2013; Limatola and Ransohoff, 2014).”
BackgroundThe Effect of Systemic Chemotherapy on Neurogenesis, Plasticity and Memory
Wigmore, P. (2012) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2012_235 · Cited by 66
Jones, H. E., Joshi, A., Shenkin, S., & Mead, G. E. (2016) · Age and Ageing · doi:10.1093/ageing/afw053 · Cited by 35
Selective serotonin reuptake inhibitors and inflammatory bowel disease; Beneficial or malpractice
Hatamnejad, M. R., Baradaran Ghavami, S., Shirvani, M., Asghari Ahmadabad, M., Shahrokh, S., Farmani, M., Sherkat, G., Asadzadeh Aghdaei, H., & Zali, M. R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.980189 · Cited by 28
Zepeda, R., Contreras, V., Pissani, C., Stack, K., Vargas, M., Owen, G. I., Lazo, O. M., & Bronfman, F. C. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.011 · Cited by 22
Patterns of antidepressant therapy and clinical outcomes among ischaemic stroke survivors
Etherton, M. R., Shah, S., Haolin, X., Xian, Y., Maisch, L., Hannah, D., Lindholm, B., Lytle, B., Thomas, L., Smith, E. E., et al. (2021) · Stroke and Vascular Neurology · doi:10.1136/svn-2020-000691 · Cited by 10
Metadata
- Authors
- Lim, C., Kim, S., Park, J., Kim, C., Yoon, S. H., & Lee, J.
- Venue
- Journal of Neuroscience Research
- Publisher
- Wiley
- Published
- 2008-10-14
- Volume
- 87
- Issue
- 4
- Pages
- 1037-1045
- ISSN
- 0360-4012 (ISSN-L)
- 1097-4547
- OpenAlex
- W2074125037
- Cited by
- 244
- References
- 3
- FWCI
- 5.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.